Type of security: Stock
Sector: Capital Goods
The data is delayed by 15 minutes.
BIO is in the long-term up 147% in 4 years.
Description: Bio-Rad Laboratories, Inc. manufactures and supplies products and systems used to separate complex chemical and biological materials, as well as to identify, analyze, and purify their components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test sy
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||2.61||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-11.92%||Sales Growth - Q/Q||-20.96%||P/E||84.52|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||3.01%||ROE||4.55%||ROI||3.44%|
|Current Ratio||4.08||Quick Ratio||2.93||Long Term Debt/Equity||0.34||Debt Ratio||0.19|
|Gross Margin||54.87%||Operating Margin||7.66%||Net Profit Margin||4.68%||Dividend Payout Ratio|
|Cash From Financing Activities||-330 K||Cash From Investing Activities||-27.99 M||Cash From Operating Activities||29.45 M||Gross Profit||270.11 M|
|Net Profit||17.82 M||Operating Profit||34.35 M||Total Assets||3.33 B||Total Current Assets||1.7 B|
|Total Current Liabilities||416.88 M||Total Debt||435.93 M||Total Liabilities||1.13 B||Total Revenue||472.82 M|
|High 52 week||306.39||Low 52 week||212.27||Last close||306.39||Last change||0.95%|
|RSI||78.16||Average true range||5.42||Beta||0.7||Volume||71.23 K|
|Simple moving average 20 days||3.17%||Simple moving average 50 days||4.15%||Simple moving average 200 days||17.51%|
|Performance Week||1.36%||Performance Month||2.17%||Performance Quart||16.83%||Performance Half||21.34%|
|Performance Year||29.83%||Performance Year-to-date||28.37%||Volatility daily||1.16%||Volatility weekly||2.6%|
|Volatility monthly||5.33%||Volatility yearly||18.46%||Relative Volume||236.57%||Average Volume||142.29 K|
|New High||0.51%||New Low|
2019-04-17 11:54:03 | Abbott ABT Q1 Earnings Beat Estimates, Organic Sales Solid
2019-04-15 19:03:00 | Bio-Rad to Report First-Quarter 2019 Financial Results
2019-04-12 09:45:01 | Weekly Jobless Claims Lowest in Nearly 50 Years: 5 Top Picks
2019-04-09 10:51:24 | See what the IHS Markit Score report has to say about Bio Rad Laboratories Inc.
2019-04-09 09:13:01 | Bio-Rad's BIO IH-500 System Secures 510K From the FDA
2019-04-09 07:30:54 | Dow Jones Futures: Zogenix Leads 3 Big Movers On FDA News
2019-04-09 00:10:54 | Dow Jones Futures: These 3 Stocks Are Big Movers Late On FDA News
2019-04-03 09:10:01 | Bio-Rad's Latest FDA Nod to Boost Clinical Diagnostics Arm
2019-04-02 17:00:00 | Bio-Rad Names Ilan Daskal Executive Vice President and Chief Financial Officer
2019-03-30 09:30:01 | Why Is Bio-Rad BIO Up 12.8% Since Last Earnings Report?
2019-03-27 07:25:00 | Recent Analysis Shows Transocean, Chipotle Mexican Grill, Marathon Oil, Laboratory Corporation of America, Bio-Rad Laboratories, and Graco Market Influences — Renewed Outlook, Key Drivers of Growth
2019-03-26 08:25:54 | See what the IHS Markit Score report has to say about Bio Rad Laboratories Inc.
2019-03-25 17:00:00 | Bio-Rad Laboratories, Inc. Receives Expected NYSE Notice Regarding Late Form 10-K Filing
2019-03-22 08:41:00 | GBT Reports Fourth Quarter and 2018 Results
2019-03-21 10:25:02 | Top Ranked Momentum Stocks to Buy for March 21st
2019-03-15 10:03:02 | Here's Why You Should Buy Masimo MASI Stock Right Now
2019-03-15 09:38:01 | Looking for a Growth Stock? Why It is Time to Focus on Bio-Rad BIO
2019-03-15 08:31:12 | BD's Venovo Gets FDA Nod, Interventional Arm to Get a Boost
2019-03-14 08:38:12 | Here's Why You Should Invest in Stryker SYK Stock Right Now
2019-03-14 08:36:12 | HEXO Catches Eye: Stock Jumps 6.6%
2019-03-12 08:45:12 | Here is Why Growth Investors Should Buy Bio-Rad BIO Now
2019-03-12 06:35:10 | Will Bio-Rad Laboratories Continue to Surge Higher?
2019-03-11 09:15:01 | Here's Why You Should Add Bio-Rad BIO to Your Portfolio
2019-03-06 10:12:03 | What Makes Bio-Rad BIO a New Strong Buy Stock
2019-03-01 07:51:12 | Bio-Rad BIO Earnings and Revenues Beat Estimates in Q4
2019-03-01 06:53:51 | Edited Transcript of BIO earnings conference call or presentation 28-Feb-19 10:00pm GMT
2019-02-28 16:38:00 | Bio-Rad Reports Fourth-Quarter and Full-Year 2018 Financial Results
2019-02-28 13:30:46 | Is Bio-Rad Laboratories, Inc. NYSE:BIO A Financially Strong Company?
2019-02-21 10:31:03 | Bio-Rad Laboratories BIO Reports Next Week: Wall Street Expects Earnings Growth
2019-02-21 08:55:01 | Will Difficult Comparison Hurt Bio-Rad's BIO Q4 Earnings?
2019-02-08 08:07:03 | See what the IHS Markit Score report has to say about Bio Rad Laboratories Inc.
2019-02-04 07:50:00 | Report: Developing Opportunities within T-Mobile US, Noble, Akebia Therapeutics, Vornado Realty Trust, Bio-Rad Laboratories, and Standex International — Future Expectations, Projections Moving into 2019
2019-01-29 10:14:29 | Bio-Rad Laboratories, Inc. NYSE:BIO: A Fundamentally Attractive Investment
2019-01-29 08:07:33 | See what the IHS Markit Score report has to say about Bio Rad Laboratories Inc.
2019-01-22 08:07:14 | See what the IHS Markit Score report has to say about Bio Rad Laboratories Inc.
2019-01-09 08:07:29 | See what the IHS Markit Score report has to say about Bio Rad Laboratories Inc.
2019-01-03 09:10:02 | Luminex Buys MilliporeSigma's Flow Cytometry Unit for $75M
2019-01-02 18:10:00 | Bio-Rad to Participate at the 37th Annual J.P. Morgan Healthcare Conference on January 8
2018-12-09 03:00:03 | Hedge Funds Are Crazy About Bio-Rad Laboratories, Inc. BIO